AKYNZEO® is a convenient combination agent available for single administration in acute or delayed CINV*

*AKYNZEO is given with dexamethasone.


AKYNZEO is available in two formulations: Capsules and For Injection

AKYNZEO CAPSULES dosing recommendations1

Chemotherapy Regimen Day 1 Days 2–4
HEC, including cisplatin-based chemotherapy AKYNZEO capsule
Dexamethasone
12 mg
Dexamethasone
8 mg
AC or other non–cisplatin-based chemotherapy AKYNZEO capsule
Dexamethasone
12 mg
  • One AKYNZEO capsule (300 mg netupitant/0.5 mg palonosetron) should be administered approximately 1 hour prior to the start of chemotherapy1
  • Dexamethasone should be administered 30 minutes prior to chemotherapy on day 11
  • AKYNZEO can be taken with or without food1
  • Avoid use in patients with severe hepatic impairment, as well as severe renal impairment or end-stage renal disease1

Akynzeo For Injection Dosing Recommendations1

Chemotherapy regimen Day 1 Days 2–4
HEC, including cisplatin-based chemotherapy AKYNZEO injection, IV over 30 min prior to therapy --
Dexamethasone 12 mg Dexamethasone 8 mg
  • AKYNZEO for injection (235 mg fosnetupitant/0.25 mg palonosetron) should be administered over 30 minutes approximately 30 minutes prior to the start of chemotherapy
  • Dexamethasone (12 mg) should be administered at the time of intravenous infusion on day 1
  • Efficacy of AKYNZEO for injection for the prevention of CINV has not been established in a clinical study of patients treated with AC or other moderately emetogenic chemotherapy
  • Avoid use in patients with severe hepatic impairment, as well as severe renal impairment or end-stage renal disease
  • Avoid use in pregnancy, limited data is available, may cause fetal harm

AC
=anthracycline-cyclophosphamide.
CINV
=chemotherapy-induced nausea and vomiting.
HEC
=highly emetogenic chemotherapy.